NCT01783639已完成不适用
The WISE Study is a Pivotal Study Evaluating the Safety and Performance of WIRION™ EPD in Patients Undergoing Carotid Artery Stenting
Gardia Medical20 个研究点 分布在 3 个国家目标入组 120 人开始时间: 2013年2月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 120
- 试验地点
- 20
- 主要终点
- The Rate of Peri-procedural (Within 30 Days of Procedure) Death, Stroke, and Myocardial Infarction.
研究概览
简要总结
The purpose of this study is to compare the safety and performance of WIRION™ EPD in patients undergoing carotid artery stenting to a performance goal based on an analysis of the results of previous US IDE carotid stenting with embolic protection studies
详细描述
Patient registry procedures include:
- Clinical Events Committee (CEC); responsibility for validating all reported primary safety outcomes
- Data Safety Monitoring Board (DSMB); to review and evaluate safety data including serious adverse events
- 100% data monitoring; to compare data entered into the registry
- Source data verification; to assess the accuracy, completeness of registry data by comparing the data to external data sources (e.g., medical records, paper or electronic case report forms).
- Standard Operating Procedures; to address registry operations and analysis activities, such as patient recruitment, data collection, data management, data analysis and reporting for adverse events.
- Sample size assessment to specify the number of participants and follow up duration.
- Data Management Plan; to address situations where variables are reported as missing, unavailable, "non-reported," uninterpretable, or considered missing because of data inconsistency or out-of-range results
- Statistical analysis plan; describing the analytical principles and statistical techniques to be employed in order to address the primary and secondary objectives, as specified in the study protocol or plan.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 years of age
- •Anticipated patient life expectancy of at least 1 year
- •Patient or authorized representative, signed a written Informed Consent form
- •Patient is willing to comply with the protocol requirements
- •Candidate for catheter-based therapy of a single stenosis located in the internal carotid artery (ICA) or the carotid bifurcation, suitable for treatment with a single FDA-approved stent with a carotid use indication
- •Reference vessel diameter for intended filter location between 3.5mm and 6.0mm
- •An adequate "landing zone" of at least 30mm
- •Patients with severe symptomatic or asymptomatic carotid artery stenosis, to be ≥ 50% for symptomatic patients OR ≥ 80% for asymptomatic patients
- •At least one high surgical risk criteria, either anatomical or co-morbid risk factors, as listed below:
- •Category I - Anatomical high risk factors
- •Recurrent stenosis after endarterectomy
- •Previous radical neck surgery or radiation therapy to the neck
- •High cervical ICA lesions or CCA lesions at or above C2 or below the clavicle
- •Spinal immobility of the neck
- •Tracheostomy or tracheal stoma
- •Any laryngeal nerve palsy and bilateral carotid artery stenosis
- •Category II - Co-morbid risk factors
- •Contralateral carotid occlusion
- •Unstable angina (Canadian Cardiovascular Society class III/IV)
- •Congestive Heart Failure (New York Heart Association functional class III/IV) and/or known severe left ventricular dysfunction LVEF<30%
- •Requires coronary artery bypass surgery, cardiac valve surgery, major vascular surgery, or abdominal aortic aneurysm repair 31-60 days post carotid stent procedure
- •Recent MI (>72 hr and <4 weeks)
- •Severe pulmonary disease with FEV1 of <30%
- •CAD in ≥2 unrevascularized vessels with stenosis ≥70%
- •Age ≥75 years
- •Uncontrolled diabetes - Female patient with no child bearing potential or has negative pregnancy test within the previous 7 days and agrees to remain on birth control throughout the study
排除标准
- •Total occlusion or near-occlusion of the target vessel
- •Severe lesion calcification
- •Presence of an alternate source of emboli
- •Presence of a filling defect, or angiographically visible thrombus, at target site
- •A greater than 50% CCA lesion proximal to the target or a distal (intracranial) lesion more severe than the target lesion
- •Evolving, acute or recent stroke within the last 30 days
- •Major stroke with a residual neurological deficit that would confound neurologic assessment
- •Vertebrobasilar insufficiency symptoms only
- •Major operation 30 days before or after the index procedure
- •Ipsilateral intracranial stenosis that requires treatment
- •Any pre-existing stent in ipsilateral carotid artery, or placement of a stent in contralateral carotid within 30 days of the index procedure
- •History of intracranial hemorrhage within 12 months
- •Any condition that precludes proper angiographic assessment or prevents femoral arterial access
- •Uncontrolled hypertension
- •Contraindication to heparin and bivalirudin, aspirin, thienopyridines
- •Known sensitivity to radiographic contrast media which cannot be controlled with pre-medication
- •History or current indication of bleeding diathesis or coagulopathy
- •Chronic renal insufficiency
- •Carotid artery dissection or aortic arch anatomical anomalies
- •Dementia or a neurological illness
- •Patient is enrolled in another drug or device study protocol that has not reached its primary endpoint
- •Severe pulmonary hypertension
- •Intra-cranial pathology (e.g., tumor, AVM. aneurysm, etc) that would make study participation inappropriate or confound neurologic assessment
研究组 & 干预措施
Arm 1
Experimental
Device: WIRION™ Embolic Protection System
Interventions: Carotid Artery Stent
干预措施: Carotid Artery Stent (Procedure)
结局指标
主要结局
The Rate of Peri-procedural (Within 30 Days of Procedure) Death, Stroke, and Myocardial Infarction.
时间窗: Within 30 Days of procedure
Each participant will be followed for 30 days of procedure during which the number of major cardiac and cerebral adverse events (Stroke, Death and Myocardial Infraction) will be counted to evaluate the device safety.
次要结局
- The Rate of Access Site Complications(Within 30 Days of procedure)
- Angiographic Success(Participants will be followed for the duration of the procedure, an expected average of 35 minutes)
- Procedural Success(Participants will be followed for the duration of the procedure, an expected average of 35 minutes)
- Neurological Events Occurring Within 30 Days Post Procedure,Including Strokes and Transient Ischemic Attacks(Within 30 Days of procedure)
- The Rate of Device Success(Participants will be followed for the duration of the procedure, an expected average of 35 minutes)
- The Rate of Clinical Success(Participants will be followed for the duration of the procedure, an expected average of 35 minutes)
研究者
研究点 (20)
Loading locations...
相似试验
已完成
不适用
SECURE®-C Cervical Artificial Disc Clinical Study/ SECURE-C Cervical Artificial Disc Postmarket Approval StudySymptomatic Cervical Disc DiseaseNCT00882661Globus Medical Inc380
已完成
3 期
Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)Gastroesophageal Reflux Disease (GERD)NCT03561883Ironwood Pharmaceuticals, Inc.609
终止
3 期
A Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)Gastroesophageal Reflux Disease (GERD)NCT03561090Ironwood Pharmaceuticals, Inc.495
已完成
3 期
Study to Evaluate Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically SuppressedChronic Hepatitis BNCT02979613Gilead Sciences490
进行中（未招募）
不适用
Cardiac Resynchronization Therapy in Previously Untreatable and High Risk Upgrade PatientsHeart FailureNCT02922036EBR Systems, Inc.300